Alzheimer's disease

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on: 
星期三, 三月 13, 2024
Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points: 
  • Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
  • The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
  • Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
  • Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.

How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?

Retrieved on: 
星期二, 三月 12, 2024
Diagnosis, Lecanemab, Alzheimer's disease, ALS, Sodium phenylbutyrate/ursodoxicoltaurine, Caregiver, Patient, Amyotrophy, News, Hope, Life, Life expectancy, Lilly, FDA, Donanemab, Pharmaceutical industry

ALS strikes adults in the prime of their life, is fatal, and the life expectancy of patients is generally 15 years or less.

Key Points: 
  • ALS strikes adults in the prime of their life, is fatal, and the life expectancy of patients is generally 15 years or less.
  • ALS patients maintain their cognitive functions while their muscle function deteriorates and eventually renders them bed-ridden, unable to swallow, and unable to breathe.
  • In an unusual decision the FDA conditionally approved Relyvrio based on the Phase 2 results as long as Phase 3 trial outcomes confirmed the results.
  • Only 40% of neurologists were initially aware of the FDA announcement regarding donanemab for Alzheimer's Disease (AD) when prompted.

National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease

Retrieved on: 
星期三, 三月 27, 2024
Seniors, Nanotechnology, Research, Software, Medical Devices, Hardware, Consumer, Genetics, Professional Services, Science, Technology, Clinical Trials, Publishing, Data Analytics, Biotechnology, Health, Communications, Health Technology, National Geographic, MicroRNA, Brain, Gene, Myenteric plexus, Gene expression, NanoString Technologies, Cell, Disease, Memory, Alzheimer's disease, Tau, Risk, Hippocampus, Inflammation, Patient, RNA, News, Federal republic, Protein, Biology, Proteomics, Publication, OTC, Ecosystem, Multimedia, SMI, Ageing

When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.

Key Points: 
  • When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.
  • (Graphic: NanoString)
    A special-interest magazine from National Geographic called Anti-Inflammation, available on newsstands this week, spotlights the role of inflammation on health and disease.
  • NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology.
  • The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere.

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

Scotland to host research challenge using the most comprehensive set of dementia biomarker data in the world

Retrieved on: 
星期一, 三月 25, 2024
Health, Neurology, Genetics, General Health, Research, Science, Biotechnology, Diagnosis, Physics, Challenge, Organization, University, Platform, GAP, Disease, Turkish coup d'état, Biomarker, Hope, Alzheimer's disease, ARC, Interim, Dementia, Hearing, Engineering, Pharmaceutical industry

The Global Alzheimer's Platform Foundation® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data Challenge 2024, a research competition using the most comprehensive set of dementia biomarker data from ground-breaking early blood testing studies for Alzheimer’s disease.

Key Points: 
  • The Global Alzheimer's Platform Foundation® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data Challenge 2024, a research competition using the most comprehensive set of dementia biomarker data from ground-breaking early blood testing studies for Alzheimer’s disease.
  • The Bio-Hermes Biomarker Data Challenge will help foster research collaboration and new insights that will likely further the collective ability to ensure effective, scalable solutions for ADRD.
  • Access to the data is open to anyone in Scotland, or their collaborators, with a question in dementia research.
  • What we have is a platform of dementia biomarker data that is truly open to anyone with a good question.

New Findings From Sunbird Bio Reveal Significant Potential of Specific Tau Proteins to Serve as Blood-Based Biomarker for Alzheimer’s Disease

Retrieved on: 
星期一, 三月 25, 2024
Oncology, Health, Neurology, General Health, Research, Science, Biotechnology, Diagnosis, EV, Brain, Plasma, Conference, Dementia, EVS, CSF, Tau, Alzheimer's disease, Sunbird, AUC, Patient, PET, Biomarker, Traffic barrier, APEX, Cerebrospinal fluid, Protein, Neuron, Trial of the century, Aggregation, DSM-IV codes, Blood, Medical imaging

“These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.

Key Points: 
  • “These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • “This confirmed correlation between EV-bound tau in the blood and tau tangles in the brain combined with the early validation of our new tau assays is incredibly exciting.
  • The Sunbird Bio study being shared at Tau2024 evaluated the potential of EV-bound tau proteins in the blood as a method of directly detecting the tau proteins that aggregate in the brain.
  • They then used Sunbird Bio’s new proprietary tau assays to distinguish between EV-bound and unbound soluble forms of tau in plasma.

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

Retrieved on: 
星期三, 三月 20, 2024
Biotechnology, Technology, Health, General Health, Pharmaceutical, Mental Health, Other Science, Other Technology, Research, Science, Clinical Trials, Agitation, AD1, Alzheimer's disease, Patient, CMAI, IGC, AAD, Caregiver burden, Dementia, Food, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).
  • The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease, indicating strong therapeutic potential for IGC-AD1.
  • "We are excited with the positive interim results from the Phase 2 trial of IGC-AD1 for agitation in dementia due to Alzheimer's disease.
  • IGC-AD1’s interim results demonstrate a clinical and statistically significant reduction in agitation compared to placebo, suggesting a strong plausibility to address a substantial unmet medical need.

New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment

Retrieved on: 
星期一, 三月 18, 2024
Mental Health, Managed Care, Medical Devices, Hospitals, Neurology, Science, Medical Supplies, Clinical Trials, Biotechnology, Health, Health Technology, Health Insurance, Other Science, Research, Radiology, Pharmaceutical, Seniors, Radiation, APS2, Certification, Brain, Alzheimer's disease, Deficit spending, Disease, Memory, AUC, Patient, Ageing, PET, Journal, Apolipoprotein, City, CLIA, Pathology, Medicare, Amyloid, Medical imaging

The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.

Key Points: 
  • The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.
  • The APS2 result was the most robust method among the individual plasma amyloid and tau analytes measured to identify disease.
  • In the published study, the PrecivityAD2 blood test was clinically validated in 583 individuals with cognitive impairment across two independent cohorts.
  • C₂N is working toward obtaining the requisite certification that will permit the PrecivityAD2 test to be available in New York in the near future.

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期一, 三月 18, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Research, Exercise, Science, Patent, Alzheimer's disease, Patient, NPC, Therapy, CYTH, FDA, Cyclo, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.
  • “Following the completion of the merger with Applied Molecular Transport, we are poised to continue building momentum and achieving the value-driving milestones ahead.
  • Net loss for the year ended December 31, 2023 was approximately $20.1 million.
  • The changes in research and development expenses resulted from the increased activity in the Company’s Phase 3 study of Trappsol® Cyclo™ for the treatment of NPC.

One Day University Transforms into Curiosity University, Strengthens Content Offering and Distribution as Subscribers Hit Pivotal Milestone

Retrieved on: 
星期四, 三月 14, 2024
Men, Online, Entertainment, Internet, Consumer, Technology, Other Education, Continuing, University, Education, Audio, Video, Women, Other Technology, ODU, Curiosity, Culture, Organization, Pulitzer, AARP, Science, Comcast, History, Pulitzer Prize, Roku, Alzheimer's disease, Content, Multimedia, One Day University, Tourism

Curiosity Inc. is announcing a significant milestone for the former One Day University, now rebranded Curiosity University , as it surpasses 100,000 paying subscribers.

Key Points: 
  • Curiosity Inc. is announcing a significant milestone for the former One Day University, now rebranded Curiosity University , as it surpasses 100,000 paying subscribers.
  • View the full release here: https://www.businesswire.com/news/home/20240314843984/en/
    Curiosity University hits 100,000 paying subscribers.
  • Curiosity U’s expanded distribution and partnerships include, among others, Comcast, Xumo, Cox, and Roku.
  • “The evolution and rebranding of Curiosity University underscores our belief in the transformative power of curiosity,” said Rob Burk, Head of Content for Curiosity.